Navigation Links
Longer Drug Regimen Still Best Against Breast Cancer
Date:6/2/2010

Giving meds sequentially, not concurrently, gives survival edge for those with early stage disease, study finds

WEDNESDAY, June 2 (HealthDay News) -- For patients with early stage breast cancer, taking chemotherapy drugs sequentially over six months helps improve their survival compared to taking them at the same time over a shorter three-month span, a new study found.

The new findings will probably come as a relief to doctors, most of whom already follow the sequential protocol, said Dr. Bhuvaneswari Ramaswamy, a breast oncologist with the Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus.

But the "most exciting and surprising finding," said study lead author Dr. Sandra M. Swain, was that younger women who went into early menopause because of their chemotherapy -- in other words, those who stopped having periods -- were more likely to live longer.

"That's something that's not been reported," added Swain, who is medical director of the Washington Cancer Institute, Washington Hospital Center in Washington, D.C.

And this was true irrespective of whether the women's cancers were estrogen-receptor positive (meaning estrogen furthers their growth) or not.

In the study, reported in the June 3 issue of the New England Journal of Medicine, the authors tracked outcomes for almost 5,400 women with early stage breast cancer that had spread to at least one lymph node.

The patients were randomly divided into one of three treatment groups: the sequential group, which involved three drugs (doxorubicin, cyclophosphamide and docetaxel) taken in sequence over six months; or one of two "concurrent" groups, where women received either two or three of these medications concurrently for three months.

After eight years of follow-up, 83 percent of patients in the sequential group were still alive compared to 79 percent of those in the concurrent groups, the authors report.

Disease-free survival was also better in the sequential group, leading to the conclusion that a longer course of treatment remains better than a shorter course, the study said.

However, an accompanying editorial in the journal pointed out that the side effects associated with the longer program might not be worth the small survival advantage for many women.

As to the issue of amenorrhea (cessation of menstrual cycles) also improving survival, Swain said, this "really generated a new hypothesis that connects cessation of menses with survival."

No periods mean less estrogen is circulating in the body and estrogen is known to fuel certain types of cancers. But that isn't a likely explanation in this study, given that amenorrhea also resulted in longer survival even in women whose tumors were estrogen-receptor (ER) negative -- that is, their cancers don't respond to estrogen.

"This [study] gives us a hint that women who stop having their periods -- even in the patients who are not ER positive -- may have a survival advantage," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

However, given that so much remains unknown, the message to women is not that suppressing ovarian function is a way to reduce their risk of breast cancer, said another study author, Dr. Charles E. Geyer Jr., director of medical affairs of the National Surgical Adjuvant Breast and Bowel Project (which conducted the trial) and vice chair of human oncology at Allegheny General Hospital in Pittsburgh.

More information

To learn more about breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Bhuvaneswari Ramaswamy, M.D., breast oncologist, Ohio State University Comprehensive Cancer Center--Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus; Sandra M. Swain, M.D., medical director, Washington Cancer Institute, Washington Hospital Center, Washington D.C.; Charles E. Geyer Jr., M.D., director of medical affairs, NSABP and vice chair of human oncology, Allegheny General Hospital, Pittsburgh; Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health System, Baton Rouge, La.; June 3, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Using Nicotine Patch Longer Boosts Efforts to Quit
2. Sedation Linked to Longer Stay in ICU
3. Zambian study finds longer breastfeeding best for HIV-infected mothers
4. Pet Health Insurance Grows as Pets Live Longer and Healthier Lives
5. Marijuana Use No Longer Dropping Among U.S. Teens
6. Looking Younger Than Your Age May Mean Longer Life
7. Military children face more emotional challenges as parental deployments grow longer, study finds
8. Glaucoma Drugs May Play Role in Longer Life
9. Biological clock could be a key to better health, longer life
10. Big Smiles, Longer Lives?
11. Perhaps a longer lifespan, certainly a longer health span
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: